Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Amendment: Patient Survival Rates in Myelodysplastic Syndrome Following Azacitidine Treatment

  • By

  • Kanticha Thammagul

  • Suppalux Limpiwattakee

  • Pichika Chantrathammachart

  • Teeraya Puavilai

  • Suporn Chuncharunee

  • Pimjai Niparuck

  • September 26, 2026

Share

Objective:

Correction of author name in the original article.

Key Findings:
  • The correct author name is Suppalux Limpiwattakee.
  • The erroneous name previously published was Suppalux Limpiwakee.
Interpretation:

The correction has been made to the original article.

Conclusion:

The authors have updated the author group to reflect the correct name.

Sources:

Original Source(s)

Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy

  • by Kanticha Thammagul, Suppalux Limpiwattakee, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee, Pimjai Niparuck

  • September 26, 2026

Related Content

MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models

Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer

  • September 24, 2026

  • 3 min
Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

Correction: Lessons Learned From Implementing a Culturally Tailored Virtual Support Program for Asian American Breast Cancer Survivors With Pain and Depression